Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by Novavax,

In recent interviews, Health and Human Services Secretary Robert F. Kennedy Jr. has minimized the risk COVID-19 poses to kids and exaggerated the risk of the vaccine, incorrectly claiming that the shot poses a “profound risk” to children.

Placebo testing has been part of the process since the 1940s. It’s unclear what additional measures would achieve — but it may slow development.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a live, weakened form of the virus to trigger immunity.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine.

"Dengue can become severe within a few hours," the advisory states. "Severe dengue is a medical emergency, usually requiring hospitalization." The full list of countries in the ad